The role of upadacitinib in the treatment of moderate-to-severe active rheumatoid arthritis

Despite recent promising developments in the treatment of rheumatoid arthritis (RA), a substantial proportion of patients still cannot achieve the treatment targets: low disease activity and remission. Janus kinase (JAK) inhibitors have the potential to fill this important gap with their high effici...

Descripción completa

Detalles Bibliográficos
Autores principales: Avci, Ali Berkant, Feist, Eugen, Burmester, Gerd Rüdiger
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8511916/
https://www.ncbi.nlm.nih.gov/pubmed/34659493
http://dx.doi.org/10.1177/1759720X211047662

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8511916/
https://www.ncbi.nlm.nih.gov/pubmed/34659493
http://dx.doi.org/10.1177/1759720X211047662

Ejemplares similares